Growth Hormone Secretagogue

Yes — and this is one of the most clinically important points for patients considering GHS therapy. The pituitary's capacity to respond to GHRH and ghrelin receptor stimulation declines with age, independently of the GH decline itself. In the forties and early fifties, pituitary responsiveness is typically still robust enough to produce meaningful GH pulse amplitude from secretagogue stimulation. By the late sixties and beyond, the pituitary's reserve capacity may be significantly diminished, producing smaller GH responses to the same dose. This is why SPOKEmed's longevity-oriented patients who are interested in GH support are best served by initiating evaluation earlier in the aging process rather than waiting until somatopause is advanced.

Direct HGH administration provides supraphysiological and non-pulsatile GH levels, bypasses the pituitary's regulatory function, and suppresses the pituitary's own GH production over time — potentially leading to pituitary atrophy. It is also a Schedule III controlled substance with strict regulatory oversight. Growth hormone secretagogues stimulate the pituitary to release its own GH in natural pulsatile patterns, working within the regulatory feedback axis rather than overriding it. This approach is considered more physiological and carries a different risk profile.

Growth hormone secretion declines progressively after approximately age 30, with total GH output reducing by roughly 14% per decade — a process called somatopause. By the sixties, GH levels may be 50% of young-adult levels. This decline is associated with loss of muscle mass, increased visceral fat, reduced bone density, diminished sleep quality (GH is secreted during deep sleep), and reduced recovery capacity. For midlife women, this GH decline compounds with the hormonal and metabolic changes of menopause — making the somatopause-menopause overlap a particularly challenging period for body composition and metabolic health.